Aura Biosciences (AURA) Other Non Operating Income (2021 - 2026)
Aura Biosciences' (AURA) quarterly Other Non Operating Income came in at $2000.0 in Q1 2026, up 108.33% YoY from $960.0 in Q1 2025, and down 98.66% on a QoQ basis from $149000.0 in Q4 2025.
Analysis
Aura Biosciences (AURA) Other Non Operating Income (2021 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 6 years of Other Non Operating Income data on file, last reported at $2000.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 108.33% year-over-year to $2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $102000.0 (up 191.07% YoY) and the FY2025 annual result came in at $77000.0, up 164.17% from the prior year.
- Other Non Operating Income fell to $2000.0 in Q1 2026, from $149000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $310000.0 in Q4 2022 to a low of -$329000.0 in Q3 2022.
- A 5-year average of -$7352.9 and a median of -$25000.0 in 2024 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income sank 732.69% — and 2025, when it jumped 502.7%.
- Tracing AURA's Other Non Operating Income over 5 years: stood at $310000.0 in 2022, then slumped by 108.39% to -$26000.0 in 2023, then sank by 42.31% to -$37000.0 in 2024, then jumped by 502.7% to $149000.0 in 2025, then tumbled by 98.66% to $2000.0 in 2026.
- The last three Other Non Operating Income figures came in at $2000.0 (Q1 2026), $149000.0 (Q4 2025), and -$13000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | Aura Biosciences | 709.58 Mn | 641.74 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 154,000.00 |
| Mar 31, 2026 | 2,000.00 |
| Dec 31, 2025 | -2.66 Mn |
| Sep 30, 2025 | -13,000.00 |
| Jun 30, 2025 | -36,000.00 |
| Mar 31, 2025 | -24,000.00 |
| Dec 31, 2024 | 3.17 Mn |
| Sep 30, 2024 | -25,000.00 |
| Jun 30, 2024 | -26,000.00 |
| Mar 31, 2024 | -32,000.00 |
| Dec 31, 2023 | -26,000.00 |
| Sep 30, 2023 | -5,000.00 |
| Jun 30, 2023 | -32,000.00 |
| Mar 31, 2023 | -13,000.00 |
| Dec 31, 2022 | 310,000.00 |
| Sep 30, 2022 | -329,000.00 |
| Jun 30, 2022 | 56,000.00 |
| Mar 31, 2022 | -44,000.00 |
| Sep 30, 2021 | 52,000.00 |
| Jun 30, 2021 | 52,000.00 |